Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GALK1 | P51570 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | TDP2 | O95551 | 3/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12149800 | 0.69 | KDM4E (0.32) | KDM4CNPC1ABL1POLBMAPT | |
| SCHEMBL12149793 | 0.62 | KDM4C (0.35) | KDM4CNPC1ABL1POLBMAPT | |
| SCHEMBL12149798 | 0.62 | TSHR (0.30) | TSHR | |
| SCHEMBL13024703 | 0.62 | SMN1; SMN2 (0.35) | KDM4CNPC1ABL1POLBMAPT | |
| SCHEMBL11825534 | 0.60 | TSHR (0.46) | POLBLMNAMPIL3MBTL1KDM4E | |
| SCHEMBL3118247 | 0.60 | HSD17B10 (0.53) | KDM4CNPC1ABL1POLBMAPT | |
| SCHEMBL13827865 | 0.60 | TSHR (0.38) | MAPTBLMLMNASMN1; SMN2KDM4E | |
| SCHEMBL20274519 | 0.59 | — | — | |
| SCHEMBL12561756 | 0.56 | — | — | |
| SCHEMBL18721823 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8637475-B1 | Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | UNIVERSITY OF CAGLIARI (IT) | 2010-12-16 | — | — | US | disclosed |
| US-7250416-B2 | Azacytosine analogs and derivatives | SUPERGEN, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070087960-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | IDENIX PHARMACEUTICALS LLC | 2007-04-19 | — | — | US | disclosed |
| US-7192936-B2 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070042940-A1 | Hepatitis C; antivirals; cytosine, uracil or thymine bases on a cyclopentane ring with optional amino acid ester to form hydroxy or phosphate in vivo | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070042939-A1 | Hepatitis C; antivirals; 8-modified,1', 2', 3' or 4'-branched purine nucleoside; treating HCV infection | IDENIX PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070032407-A1 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027065-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032449-A1 | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | PNP, UGT1A3, SLC29A2 | KDM4C 2178/4885NPC1 311/4885ABL1 822/4885 |
| US-20070027066-A1 | 2' and/or 3' prodrug of 6-modified, 1', 2', 3' or 4'-branched pyrimidine nucleoside for the treatment of a Flaviviridae infection, such as a hepatitis C virus infection; 3'-L-valine ester of .beta.-D-2',6-dimethyl-cytidine; Flaviviridae polymerase inhibitors; low toxicity to host | DCTD, DIMT1, CYP2D6 | KDM4C 1270/4885NPC1 978/4885ABL1 936/4885 |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | KDM4C 2312/4885NPC1 382/4885ABL1 703/4885 |
| US-20140113880-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | KDM4C 2178/4885NPC1 311/4885ABL1 822/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | KDM4C 4238/4885NPC1 20/4885ABL1 1513/4885 |
| US-20070027104-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | KDM4C 2178/4885NPC1 311/4885ABL1 822/4885 |
| US-20130330297-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | KDM4C 1665/4885NPC1 474/4885ABL1 1021/4885 |
| US-20070042940-A1 | Hepatitis C; antivirals; cytosine, uracil or thymine bases on a cyclopentane ring with optional amino acid ester to form hydroxy or phosphate in vivo | TYMP, NUDT1, MTAP | KDM4C 1352/4885NPC1 2240/4885ABL1 812/4885 |
| US-20070032407-A1 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | NUDT1, MTAP, HAVCR2 | KDM4C 2047/4885NPC1 1107/4885ABL1 777/4885 |
| US-20070087960-A1 | Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase | HAVCR2, UGT1A3, UGT1A1 | KDM4C 1969/4885NPC1 410/4885ABL1 420/4885 |
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | KDM4C 1665/4885NPC1 474/4885ABL1 1021/4885 |
| US-20070042939-A1 | Hepatitis C; antivirals; 8-modified,1', 2', 3' or 4'-branched purine nucleoside; treating HCV infection | PNP, SLC28A1, SLC29A1 | KDM4C 1394/4885NPC1 375/4885ABL1 960/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | KDM4C 4238/4885NPC1 20/4885ABL1 1513/4885 |
| US-20070027065-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | KDM4C 2178/4885NPC1 311/4885ABL1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.